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During organogenesis, immunosurveillance, and inflammation,
chemokines selectively recruit leukocytes by activating seven-
transmembrane-spanning receptors. It has been suggested that an
important component of this process is the formation of a hapto-
tactic gradient by immobilization of chemokines on cell surface
glycosaminoglycans (GAGs). However, this hypothesis has not
been experimentally demonstrated in vivo. In the present study we
investigated the effect of mutations in the GAG binding sites
of three chemokines, monocyte chemoattractant protein-1CC
chemokine ligand (CCL)2, macrophage-inflammatory protein-1
CCL4, and RANTESCCL5, on their ability to recruit cells in vivo.
These mutant chemokines retain chemotactic activity in vitro, but
they are unable to recruit cells when administered intraperitone-
ally. Additionally, monomeric variants, although fully active in
vitro, are devoid of activity in vivo. These data demonstrate that
both GAG binding and the ability to form higher-order oligomers
are essential for the activity of particular chemokines in vivo,
although they are not required for receptor activation in vitro.
Thus, quaternary structure of chemokines and their interaction
with GAGs may significantly contribute to the localization of
leukocytes beyond migration patterns defined by chemokine re-
ceptor interactions.
Cellular migration of leukocyte populations occurs duringboth routine immunosurveillance and inflammation and is
orchestrated by several families of proteins, including proinflam-
matory cytokines, adhesion molecules, and matrix metal-
loproteases. However, chemokines control the direction of cell
migration and provide a trigger for cell activation. The immo-
bilization of chemokines on glycosaminoglycans (GAGs) of the
extracellular matrix and endothelial cell surfaces is thought to be
an essential part of this process (1).
Chemokines are a superfamily of small proteins (100 resi-
dues), which number 40 in humans (2). Their activities are
mediated through G protein-coupled seven-transmembrane re-
ceptors, of which 19 have been identified. Many chemokines bind
several receptors and multiple chemokines often bind the same
receptor, resulting in a highly complex network of interactions
(3). The majority of chemokines [macrophage-inflammatory
protein (MIP)-1CC chemokine ligand (CCL)3 and MIP-1
CCL4 being exceptions] are basic proteins, whereas the extra-
cellular domains of their receptors are acidic; thus, it is not
surprising that chemokines are also able to bind linear sulfated
GAGs such as heparin and heparan sulfate. Immobilization of
chemokines to endothelial surfaces by proteoglycans has been
demonstrated both in vitro (4) and in vivo (1, 5). This interaction
is thought to facilitate the retention of chemokines on cell
surfaces and enable localized high concentrations of chemokines
to form, even in the presence of shear forces caused by blood
flow in capillary beds. However, the biological relevance of the
GAG interaction has not been demonstrated.
Chemokines have been traditionally divided into four families
(CXC, CC, C, and CX3C) based on the patterns of amino-
terminal cysteine residues. Despite sequence identities that can
be as low as 20%, a remarkably conserved three-dimensional
tertiary structure exists across the four families. Many chemo-
kines also form dimers or higher-order oligomers. However, the
dissociation constants for dimerization are at least two orders of
magnitude higher than the concentrations required for maximal
biological activity in vitro (6). Furthermore, several studies have
shown that variants of chemokines with altered dimer interfaces
remain monomeric even at high protein concentrations and yet
are indistinguishable from wild-type chemokines in receptor
binding and activation assays in vitro. For example, N-
methylation of Leu-25 in the CXC chemokine IL-8CXC che-
mokine ligand 8 produces a monomer that is fully functional in
vitro (7). Similarly, mutation of Pro-8 to Ala in both monocyte
chemoattractant protein (MCP)-1CCL2 (8) and MIP-1
CCL4 (9) produces monomeric variants that are indistinguish-
able from wild type. Thus, like GAG binding, the physiolog-
ical significance of quaternary structure has not been fully
elucidated.
In this study, the in vivo role of chemokine GAG binding and
oligomerization was addressed by using variants engineered for
reduced ability to bind GAGs and to oligomerize. We have
studied three chemokines: MCP-1CCL2, which binds selec-
tively to CC chemokine receptor (CCR)2; MIP-1CCL4, which
binds selectively to CCR5; and RANTESCCL5, which binds to
CCR1, CCR3, and CCR5.
Materials and Methods
Production of Chemokines. Recombinant wild-type RANTES (10),
MCP-1 (11), and MIP-1 (9) were produced as described. The
[44AANA47]-RANTES mutant was generated by PCR mutagen-
esis in a two-step reaction by using two oligonucleotide pairs:
GTTGGCACACACTTGCGCGTTCGCCGCGGTGAC-
AAAGACGAC in combination with an N-terminal forward
primer and GTCGTCTTTGTCACCGCGGCGAACGCG-
CAAGTGTGTGCCAAC in combination with a C-terminal
reverse primer. The PCR product was purified and digested with
BspHI and XhoI restriction endonucleases, cloned into the NcoI
and XhoI sites of pET24d, and transformed into TG1-competent
cells. After confirmation of the correct DNA sequence, the
resulting vector was transformed into BL21(DE3)pLysS Esche-
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richia coli cells. The protein was expressed and purified as
described (10). [18AA19]-MCP-1 and [45AASA48]-MIP-1 were
produced by using described strategies (8, 9). [Nme-7T]-
RANTES was synthesized by using tBoc chemistry in a manner
similar to an N-methylated variant of IL-8 (7, 12). Eotaxin,
MCP-3, and I-309 were purchased from PeproTech (Rocky
Hill, NJ).
Heparin Binding Assays. Heparin binding (13) was assessed by
incubating increasing concentrations of chemokine with [3H]he-
parin (50 ngml) in 96-well filter plates for 1 h at 37°C. The
solutions were transferred to 96-well plates fitted with Whatman
cellulose phosphate filters and washed three times with PBS
under vacuum. After the addition of 50 l of scintillant, radio-
activity was counted. An aggregation assay on immobilized
heparin was performed as described (4) by using heparin beads
incubated with 0.1 nM 125I-labeled chemokine (custom labeled
by Amersham Pharmacia) in the presence of increasing concen-
trations of unlabeled chemokine.
Chemokine–Chinese Hamster Ovary (CHO) Cell Binding. Wild-type
CHO cells were used to assess RANTES binding to cell surface
GAGs by flow cytometry. Cells were incubated at 4°C overnight
with 1 and 0.1 M RANTES or [44AANA47]-RANTES. A
mouse monoclonal antibody directed against RANTES (a gift
from Dr. Matthias Mack, University of Munich) was used as the
primary detection antibody, and a goat anti-mouse IgG-FITC
(Silenus, Hawthorn, Australia) was used to reveal binding.
Fluorescence was measured by using a FACSCalibur (Becton
Dickinson).
In Vitro Chemotaxis. Chemotaxis was assayed in 96-well ChemoTx
plates (Neuroprobe, Cabin John, MD) by using 8-m pores for
the L1.2CCR5 transfectants and 5-m pores for the THP-1
cells. A total of 3  105 cells (L1.2CCR5 transfectants for
RANTES and MIP-1 and the promonocytic THP-1 cell line for
MCP-1) were placed in the upper chambers. Chemokines were
placed in the lower wells with appropriate dilutions, and the
chambers were incubated for 2 h at 37°C. The bottom wells
containing the migrated cells were transferred to a black 96-well
plate (Costar), frozen at 80°C for 2 h, and thawed, and the
number of cells was measured by using the cell proliferation
assay CyQUANT kit (Molecular Probes). Measurements were
done in triplicate.
Peritoneal Cell Recruitment. Eight- to 12-week-old female Balbc
mice (Janvier, Le Genest St Isle, France) were injected intra-
peritoneally with 200 l of NaCl (0.9%, lipopolysaccharide-free)
or chemokine diluted into 200 l of NaCl (0.9%, lipopolysac-
charide-free). At 18 h postinjection mice were killed by CO2
asphyxiation, the peritoneal cavity was washed three times with
5 ml of ice-cold PBS, and the total lavage was pooled for
individual mice. Total cells collected were counted with a
hemocytometer (Neubauer, Hausser Scientific Company, Hor-
sham, PA).
Statistical Tests. Statistically significant in vivo cell recruitment
was tested by one-way ANOVA, with a Bonferroni post test to
Fig. 1. (a–c) Comparison of the ability of wild-type chemokines RANTES, MIP-1, and MCP-1 (open circles) and the mutants [44AANA44]-RANTES, [18AA19]-MCP-1,
and [45AASA48]-MIP-1 (filled circles) to bind [3H]heparin. RANTES binds approximately three and five times as much heparin as MCP-1 and MIP-1, respectively.
These results are consistent with their elution pattern on heparin Sepharose affinity chromatography (results not shown). The three mutants show significant
losses of heparin binding, but [44AANA47]-RANTES and [18AA19]-MCP-1 retain 25–30% binding capacity, whereas heparin binding is completely abrogated in the
[45AASA48]-MIP-1mutant. (d) Flow cytometric analysis of the binding of wild-type RANTES and [44AANA47]-RANTES to cell surface GAGs using CHO cells. Bound
protein was detected with an anti-RANTES mAb; goat anti-mouse IgG-FITC was used to reveal bound protein. Wild-type RANTES is shown in black and
[44AANA47]-RANTES is shown in gray. The concentrations used were 1 M (solid lines) and 0.1 M (dotted lines). The shaded area represents secondary antibody
binding control.
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compare each treatment with baseline (NaCl). Levels of signif-
icance were assigned as follows: P  0.05, not significant; *, P 
0.05; **, P  0.01; ***, P  0.001.
Results and Discussion
Characterization of the GAG Binding Sites of Chemokines. Residues
important for the interaction of chemokines with GAGs have
been defined for several chemokines by mutagenesis and in vitro
heparinheparan sulfate binding assays. In some cases, the
binding site is spatially distinct from the G protein-coupled
receptor binding site(s). Examples include K58 and H66 in the
C-terminal domain of MCP-1 (13), K64 and R68 in the C-
terminal domain of IL-8 (14), and a BBXB motif (B represents
a basic residue) in the 20s loop of stromal cell-derived factor-
1CXC chemokine ligand 12 (15). For others there is partial
overlap of the GAG and receptor binding sites. The principal
heparin binding region of RANTES, MIP-1, and MIP-1
involves a classical BBXB cluster in the 40s loop (16–18) that is
also implicated in receptor binding. A GAG mutant of RANTES
with a triple mutation, [44AANA47]-RANTES, retains high-
affinity binding to CCR5 but has a 200-fold decrease in CCR1
binding (16, 19). In the case of MIP-1 and MIP-1, mutation
of the BBXB motif in the 40s loop causes a significant decrease
in receptor binding affinity (17, 18). For MCP-1, we show here
that R18 and K19 participate in GAG binding in addition to
residues K58 and H66 in the C-terminal helix (13). The single
mutations, R18A and K19A, make small contributions to recep-
tor binding (11), and the double mutant [18AA19]-MCP-1 shows
only a 20-fold decrease in affinity for CCR2 (IC50  1.4 nM
versus 0.08 nM for wild type; results not shown).
As illustrated in Fig. 1, a tritiated heparin binding assay (13)
demonstrated that RANTES has the highest heparin binding
capacity among the three chemokines, with MIP-1  being the
weakest, in accordance with its acidic pI. However, the fact that
MIP-1 (and MIP-1) binds heparin at all suggests that the
chemokineheparin interaction is not due only to nonspecific
electrostatic interactions; it has specificity. As previously re-
ported, [44AANA47]-RANTES retains some residual affinity for
heparin (16). The same is true for [18AA19]-MCP-1. By contrast,
heparin binding of [45AASA48]-MIP-1 is completely abrogated
(Fig. 1c).
One potential caveat to these in vitro assays is in the use of
heparin rather than the perhaps more physiologically relevant
cell surface GAGs such as heparan sulfate. However, heparin is
believed to be structurally and chemically similar enough to
heparan sulfate to serve as a good substitute, at least in a first
Fig. 2. (a) In vitro chemotaxis assays show that each GAG-binding mutant (filled circles) retains the ability to elicit a robust chemotactic response compared
with the wild-type chemokines (open circles). Chemotaxis of the [44AANA47]-RANTES and [45AASA48]-MIP-1mutants was measured on L1.2CCR5 transfectants,
and [18AA19]-MCP-1 was measured by using the promonocytic THP-1 cell line, which expresses CCR2. The three mutants have small losses of receptor affinity (3-,
20-, and 77-fold for [44AANA44]-RANTES, [18AA19]-MCP-1, and [45AASA48]-MIP-1, respectively), as reflected in their EC50 values. (b) An in vivo dose–response curve
for RANTES shows that recruitment of cells into the peritoneum is maximal at the 10-g dose. Cells were counted 18 h after administration of chemokine. (c)
Intraperitoneal recruitment elicited by the mutants (filled circles) in comparison to wild-type chemokines (open circles). In view of the small reduction in efficacy
observed in vitro, two of the mutants, [44AANA47]-RANTES and [18AA19]-MCP-1, were tested at a 100-g dose (filled diamonds) but still did not recruit.
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approach. Furthermore, chemokine binding to extracellular
matrix and other structures has been shown to correlate strongly
with the avidity of binding to heparin in vitro (20). Along the
same lines, Fig. 1d shows that wild-type RANTES binds strongly
to CHO cells lacking chemokine receptors, whereas
[44AANA47]-RANTES binds poorly, paralleling its reduced
heparin-binding capacity. Thus, the heparin assays appear to be
reasonable predictors of the behavior of the mutants toward
other types of GAG surfaces.
In Vitro and in Vivo Activity of GAG Binding Site Mutants. Impor-
tantly, the GAG binding site mutants maintain the ability to
induce chemotaxis in vitro (Fig. 2a). The in vitro assay involves
the establishment of an artificial gradient, produced in a stan-
dard chemotaxis apparatus by placing chemokine in a lower
chamber and cells in an upper chamber, separated by a porous
membrane. Restricting the chemokine to a microchamber, cou-
pled with a lack of flow conditions, apparently eliminates the
necessity for immobilization on GAGs. Thus, the three mutants,
despite their significantly compromised GAG binding, show
robust chemotaxis profiles in vitro (Fig. 2a). The losses in
potency can be attributed to the small losses of receptor affinity
and to the impaired interaction with GAGs on the recruited
cells, because GAGs can enhance the localization of chemokine
to these cells in vitro (21). Thus, these chemokine variants show
significant reductions in GAG binding but retain chemotactic
activity in vitro, making them ideal reagents for testing the
importance of GAG binding in vivo.
To test the role of GAG binding in vivo, wild-type or mutant
chemokine was injected into the peritoneal cavity of Balbc
mice. Maximal recruitment was determined to be 18 h postin-
jection of wild-type chemokine for a 10-g dose, because the
number of cells increased linearly over the range of 10 ng to 10
g, with no further increase up to 100 g (Fig. 2b); thus, 10 g
per mouse was used in all subsequent experiments. As shown in
Fig. 2c, all three wild-type chemokines induced a robust increase
in the number of recruited cells to a level approximately two- to
threefold over the control. However, no recruitment was ob-
served for the GAG binding site mutants compared with the
saline controls (Fig. 2c). Because these mutants had some
reduction in chemotactic activity in vitro, two ([44AANA47]-
RANTES and [18AA19]-MCP-1) were tested at a dose of 100 g,
Fig. 3. Characterization of monomeric variants. (a) Binding of [Nme-7T]-RANTES, [Ala-8]-MCP-1, and [Ala-8]-MIP-1 (filled circles) to [3H]heparin in comparison
to wild-type chemokines (open circles). (b) Ability of [Nme-7T]-RANTES (filled circles) to oligomerize on heparin beads compared with wild-type RANTES (open
circles). (c) Equilibrium competition binding assays of [Nme-7T]-RANTES (filled circles) and wild-type RANTES (open circles) using CHO membranes expressing CCR1
and CCR5. (d) In vitro chemotaxis activity of L1.2CCR5 transfectants in response to [Nme-7T]-RANTES, [Ala-8]-MIP-1 (filled circles), and wild-type chemokines
(open circles).
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which is 10,000-fold higher than that at which the wild-type
chemokines showed measurable recruitment; yet still no activity
was observed (Fig. 2c). These results demonstrate that interac-
tion with GAGs in vivo is indeed essential, in contrast to the
in vitro chemotaxis assay.
The Role of Oligomerization. Next, the relevance of oligomerization
to in vivo chemotaxis was addressed. These studies were moti-
vated by the observation that certain chemokines form dimers or
tetramers in solution, whereas others form large oligomers that
attain a mass between 100 and 200 kDa (6). Additionally,
heparin has been shown to induce higher-order aggregates in
solution in vitro (4), and -chemokines secreted from cytotoxic
T cells have been observed as large as 400–600 kDa in complex
with sulfated proteoglycans (22). Chemokine oligomerization
can also be observed on immobilized heparin or cell surface
proteoglycans (4). Although chemokine oligomerization is not
important for receptor activation as indicated by several in vitro
studies using monomeric variants (8, 9, 12), these heparin
proteoglycan interactions suggest that it may be important in vivo
via a mechanism involving GAG binding.
To investigate this hypothesis, we examined the in vivo che-
motaxis behavior of previously reported monomeric mutants of
MCP-1 ([Ala-8]-MCP-1), MIP-1 ([Ala-8]-MIP-1), and a
chemically synthesized variant of RANTES that was N-
methylated on the amide nitrogen of Thr-7 ([Nme-7T]-
RANTES). The first two mutants are monomeric at or above 1.0
mM concentrations (8, 9). The RANTES analogue was pre-
dicted to be monomeric because the N-methyl group should
prevent hydrogen bonding across the -sheet dimer interface,
similar to a previously reported IL-8 variant (7). This hypothesis
was confirmed by analytical ultracentrifugation, which suggested
a mass of 10.6 kDa at 10 M chemokine (data not shown),
consistent with a predominantly monomeric state (expected
mass 7,865 Da). Moreover, [Nme-7T]-RANTES was unable to
oligomerize on immobilized GAGs (Fig. 3b) in contrast to
wild-type RANTES and other chemokines (4). These mono-
meric variants retain the ability to bind heparin, but with reduced
capacity relative to the wild-type proteins that form dimers at the
concentrations used in this assay (Fig. 3a). As has been reported
for [Ala-8]-MCP-1 (8) and [Ala-8]-MIP-1 (9), which show
wild-type affinities in receptor binding assays, [Nme-7T]-
RANTES retains wild-type receptor binding to CCR1 and
CCR5 (Fig. 3c). Full activity in in vitro chemotaxis is shown for
all three of these proteins (Fig. 3d and ref. 8). Nevertheless,
despite the ability to bind and activate their receptors as well as
an ability to bind to heparin, the inability to recruit cells in vivo
(Fig. 4a) demonstrates that oligomerization is critical for these
three chemokines. Interestingly, like [Nme-7T]-RANTES, the
GAG binding mutant, [44AANA47]-RANTES, is also unable to
oligomerize on immobilized heparin (data not shown).
A minimal oligomerization state is also suggested by the in vivo
activity of other RANTES mutants. [Ala-66]-RANTES has been
reported to form dimers whereas [Ala-26]-RANTES forms
tetramers, but neither forms higher-order oligomers in solution
(6). Interestingly, the dimeric form of RANTES was devoid of
activity, whereas the tetramer was fully active (Fig. 4c), indicat-
ing that a tetramer may be required for in vivo activity of this
chemokine. On the other hand, certain chemokines, such as
MCP-3CCL7, eotaxinCCL11, and I-309CCL-1, appear to be
naturally occurring monomers, because structural and biophys-
ical studies have failed to provide evidence of oligomerization
(23–25). Nevertheless, eotaxin has activity when administered
into guinea pig skin (26), and we have shown here that it is also
active in the peritoneal cavity recruitment assay (Fig. 4b).
Similarly, MCP-3 and I-309 are fully active (Fig. 4b). However,
it is not known whether these chemokines oligomerize on cell
surface proteoglycans.
Fig. 4. Ability of oligomerization mutants to recruit cells into the peritoneal
cavity. (a) Wild-type chemokine (open circles) administered at a dose of 10 g
shows a robust response, whereas the monomeric mutants [Nme-7T]-RANTES,
[Ala-8]-MCP-1, and [Ala-8]-MIP-1 (filled circles) are devoid of activity when
administered at the same dose. (b) Three naturally occurring monomeric
chemokines, I-309, MCP-3, and eotaxin, are active in the recruitment assay
(10-g dose). (c) Comparison of wild-type RANTES, a synthetic monomer
([Nme-7T]-RANTES), a dimeric RANTES mutant ([Ala-66]-RANTES), and a tet-
rameric mutant ([Ala-26]-RANTES) in the recruitment assay (10-g dose). Of
the mutants, only the tetramer recruits, suggesting a minimal oligomerization
state for in vivo activity.
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Thus, oligomerization may be important only for some che-
mokines, and this requirement, or lack thereof, may have
functional implications andor depend on the site of production.
The simplest explanation for these results is that chemokines that
are functional in recruiting cells from the circulation into the
underlying tissue may require oligomerization to function under
flow conditions, whereas those produced within the extravascu-
lar space may not. A more intriguing hypothesis is that chemo-
kines whose GAG binding sites overlap with receptor binding
sites, as is the case for RANTES, MCP-1, and MIP1-, may
require oligomerization to bind GAGs through some of the
subunits while exposing other subunit binding sites to the
receptor. Interaction of chemokine through the exposed binding
site could then trigger release of chemokine monomers, allowing
the entire binding site, which is partially buried in the oligomers,
to interact with the receptor (8).
Summary
We believe that this is the first formal demonstration that GAG
binding is a prerequisite of chemokine activity in vivo, even
though it is not required for receptor activation. Without this
tethering mechanism, chemokines would be washed away from
the local production site, especially under flow conditions,
diluted to a concentration below the threshold required for
binding, and distributed uniformly throughout the vasculature
such that no localized chemotactic signal is generated for
leukocytes to follow. These results also suggest an additional
level of specificity to this system, generally perceived as redun-
dant, where certain chemokines need to oligomerize for their in
vivo function. Not only do these results show that GAG binding
and chemokine oligomerization are essential for the chemotactic
properties of chemokines, but they suggest plausible mechanisms
for functional specificity involving GAGs that may be operative
in other complex cytokine networks. Finally, the results suggest
new strategies based on these mechanistic observations to in-
terfere with chemokine function for the treatment of disease.
We dedicate this work to Dr. Ian Clark-Lewis, who passed away
December 30, 2002. T.M.H. gratefully acknowledges support from the
National Institutes of Health and the American Heart Association.
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